Literature DB >> 22677920

Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.

M Vaneckova1, T Kalincik, J Krasensky, D Horakova, E Havrdova, T Hrebikova, Z Seidl.   

Abstract

AIM: To determine whether corpus callosum atrophy predicts future clinical deterioration in multiple sclerosis.
METHODS: In 39 multiple sclerosis patients the area of corpus callosum in the sagittal plane, T2 and T1 lesion volumes, brain parenchymal fraction and brain atrophy were determined at baseline and 1 year after treatment initiation. Non-parametric and multiple regression models were built to identify the most reliable predictors of disability and of its changes over 9 years.
RESULTS: Corpus callosum atrophy during the first year of treatment was the best predictor of disability (r = -0.56) and of its increase at 9 years (r = 0.65). Corpus callosum atrophy of at least 2% predicted increase in disability with 93% sensitivity and 73% specificity (odds ratio = 35).
CONCLUSION: Corpus callosum atrophy is a simple and accurate predictor of future disability accumulation and is feasible for routine clinical practice.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22677920     DOI: 10.1159/000337683

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  9 in total

1.  Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.

Authors:  Eva Hynčicová; Martin Vyhnálek; Adam Kalina; Lukáš Martinkovič; Tomáš Nikolai; Jiří Lisý; Jakub Hort; Eva Meluzínová; Jan Laczó
Journal:  J Neurol       Date:  2016-12-27       Impact factor: 4.849

2.  Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Authors:  A Burgetova; P Dusek; M Vaneckova; D Horakova; C Langkammer; J Krasensky; L Sobisek; P Matras; M Masek; Z Seidl
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

3.  Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis.

Authors:  Eric C Klawiter; Antonia Ceccarelli; Ashish Arora; Jonathan Jackson; Sonya Bakshi; Gloria Kim; Jennifer Miller; Shahamat Tauhid; Christian von Gizycki; Rohit Bakshi; Mohit Neema
Journal:  J Neuroimaging       Date:  2014-05-09       Impact factor: 2.486

4.  A surface-based technique for mapping homotopic interhemispheric connectivity: Development, characterization, and clinical application.

Authors:  Sean M Tobyne; Daria Boratyn; Jessica A Johnson; Douglas N Greve; Caterina Mainero; Eric C Klawiter
Journal:  Hum Brain Mapp       Date:  2016-05-24       Impact factor: 5.038

5.  Perivascular space is associated with brain atrophy in patients with multiple sclerosis.

Authors:  Xue-Yu Liu; Gai-Ying Ma; Shi Wang; Qian Gao; Cong Guo; Qiao Wei; Xuan Zhou; Li-Ping Chen
Journal:  Quant Imaging Med Surg       Date:  2022-02

6.  Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.

Authors:  Tomas Kalincik; Manuela Vaneckova; Michaela Tyblova; Jan Krasensky; Zdenek Seidl; Eva Havrdova; Dana Horakova
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

7.  Reliability of measuring regional callosal atrophy in neurodegenerative diseases.

Authors:  Jeroen Van Schependom; Saurabh Jain; Melissa Cambron; Anne-Marie Vanbinst; Johan De Mey; Dirk Smeets; Guy Nagels
Journal:  Neuroimage Clin       Date:  2016-10-15       Impact factor: 4.881

8.  Grey matter atrophy in patients with benign multiple sclerosis.

Authors:  Marja Niiranen; Juha Koikkalainen; Jyrki Lötjönen; Tuomas Selander; Antti Cajanus; Päivi Hartikainen; Sakari Simula; Ritva Vanninen; Anne M Remes
Journal:  Brain Behav       Date:  2022-06-28       Impact factor: 3.405

9.  MRI-Based Brain Volumetry at a Single Time Point Complements Clinical Evaluation of Patients With Multiple Sclerosis in an Outpatient Setting.

Authors:  Alaleh Raji; Ann-Christin Ostwaldt; Roland Opfer; Per Suppa; Lothar Spies; Gerhard Winkler
Journal:  Front Neurol       Date:  2018-07-25       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.